By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories and Tarrot Laboratories today announced an exclusive research collaboration and license agreement to identify biomarkers associated with clinical response to anti-TNF therapies in Crohn's disease.

The deal covers genetic and serologic biomarkers as predictors of response to drugs such as Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab). Diagnostic tests would be developed from the biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.